HIV‐associated nephropathy: A decade of clinical outcomes, global disparities and emerging promise
7 affiliations
- 1Department of Medicine University of Cambridge Cambridge UK
- 2Cambridge University Hospitals NHS Foundation Trust Cambridge UK
- 3University of Cape Town Cape Town South Africa
- 4National Health Laboratory Service (NHLS), University of Cape Town Cape Town South Africa
- 5Kings College London London UK
- 6Kings College Hospital NHS Foundation Trust London UK
- 7Department of Pathology University of Cambridge Cambridge UK
Abstract
Objective: To review the pathogenesis, epidemiology, clinical presentation, management and outcomes of HIV‐associated nephropathy (HIVAN), with emphasis on global disparities, genetic susceptibility (APOL1) and emerging therapeutic and technological advances.
Design: Narrative literature review synthesizing contemporary evidence from clinical cohorts, translational research and guideline‐based practice, with comparative perspectives from high‐resource (UK) and low‐resource (sub‐Saharan Africa) settings.
Methods: Relevant studies were analysed to evaluate mechanisms of disease, epidemiological trends, diagnostic approaches, treatment strategies and long‐term outcomes. Particular focus was placed on APOL1‐associated risk, antiretroviral therapy (ART) impact and recent developments including artificial intelligence (AI) applications and targeted therapies.
Results: HIVAN arises from direct HIV infection of renal epithelial cells in genetically susceptible individuals, particularly those with APOL1 risk variants. ART has significantly reduced incidence in high‐income settings, whereas HIVAN remains prevalent in sub‐Saharan Africa due to delayed diagnosis and limited healthcare access. Clinically, HIVAN presents with proteinuria and progressive kidney dysfunction, requiring biopsy for confirmation. Early ART initiation improves renal outcomes, supported by adjunctive therapies such as renin‐angiotensin system blockade and SGLT2 inhibitors. Emerging therapies targeting APOL1 and advances in AI‐driven risk prediction and diagnostics show promise.
Conclusions: HIVAN reflects an interplay between viral, genetic and socio‐economic factors. While ART has transformed outcomes in well‐resourced settings, significant global disparities persist. Future progress depends on improving HIV care access, expanding renal services and advancing precision medicine approaches, including APOL1‐targeted therapies and AI‐enabled risk stratification.
Related
- Ultrasound-guided hydrodissection combined with radiofrequency for refractory occipital neuralgia: clinical outcomes, durability, and factors associated with repeat intervention
- Integrating Single-Molecule Variant Phenotyping with Clinical Features Predicts Outcomes in KIF1A-Associated Neurological Disorder
- Triple Renal Pathology in a Patient With Myeloperoxidase-Associated Vasculitis, Diabetic Nephropathy, and Immunoglobulin A Nephropathy: A Case Report
- Clinical Outcomes and Safety Associated with Adjunctive Antibiotic-Loaded Calcium Sulphate Beads in Hip and Knee Periprosthetic Joint Infection: A Systematic Review
- Emerging Biomarkers in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Current Evidence, Clinical Utility, and Future Perspectives.
BibTeX
@article{pathiyil2026hivassociated,
title = {{HIV‐associated nephropathy: A decade of clinical outcomes, global disparities and emerging promise}},
author = {Deepak V. Pathiyil and Nicola Wearne and Brendon Price and Frank Post and Dami A. Collier},
journal = {HIV Medicine},
year = {2026},
month = sep,
doi = {10.1111/hiv.70315},
url = {https://doi.org/10.1111/hiv.70315},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - HIV‐associated nephropathy: A decade of clinical outcomes, global disparities and emerging promise
AU - Deepak V. Pathiyil
AU - Nicola Wearne
AU - Brendon Price
AU - Frank Post
AU - Dami A. Collier
PY - 2026
DA - 2026/09/29
JO - HIV Medicine
DO - 10.1111/hiv.70315
UR - https://doi.org/10.1111/hiv.70315
AB - Objective: To review the pathogenesis, epidemiology, clinical presentation, management and outcomes of HIV‐associated nephropathy (HIVAN), with emphasis on global disparities, genetic susceptibility (APOL1) and emerging therapeutic and technological advances. Design: Narrative literature review synthesizing contemporary evidence from clinical cohorts, translational research and guideline‐based practice, with comparative perspectives from high‐resource (UK) and low‐resource (sub‐Saharan Africa) settings. Methods: Relevant studies were analysed to evaluate mechanisms of disease, epidemiological trends, diagnostic approaches, treatment strategies and long‐term outcomes. Particular focus was placed on APOL1‐associated risk, antiretroviral therapy (ART) impact and recent developments including artificial intelligence (AI) applications and targeted therapies. Results: HIVAN arises from direct HIV infection of renal epithelial cells in genetically susceptible individuals, particularly those with APOL1 risk variants. ART has significantly reduced incidence in high‐income settings, whereas HIVAN remains prevalent in sub‐Saharan Africa due to delayed diagnosis and limited healthcare access. Clinically, HIVAN presents with proteinuria and progressive kidney dysfunction, requiring biopsy for confirmation. Early ART initiation improves renal outcomes, supported by adjunctive therapies such as renin‐angiotensin system blockade and SGLT2 inhibitors. Emerging therapies targeting APOL1 and advances in AI‐driven risk prediction and diagnostics show promise. Conclusions: HIVAN reflects an interplay between viral, genetic and socio‐economic factors. While ART has transformed outcomes in well‐resourced settings, significant global disparities persist. Future progress depends on improving HIV care access, expanding renal services and advancing precision medicine approaches, including APOL1‐targeted therapies and AI‐enabled risk stratification.
SN - 1464-2662
SN - 1468-1293
ER -